An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

Solid Tumor Clinical Trial

Official title:

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05166070
• Other study ID #: RD133CI002
• Status: Recruiting
• Phase: Early Phase 1
• Start date: January 1, 2022
• Est. completion date: January 1, 2037

Study information

• Verified date: December 2021
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Lingxiang Liu
• Email: llxlau[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted. The main purpose is to evaluate the safety of RD133 in the treatment of subjects with relapsed or refractory MSLN-positive solid tumors and explore the Recommend phase II dose of RD133 in the treatment of patients with relapsed/refractory MSLN-positive solid tumors.

Description:

Leukapheresis procedure will be performed to manufacture RD133 chimeric antigen receptor (CAR) modified T cells. Bridging therapy is allowed between PBMC collection and lymphodepletion. Lymphodepletion with fludarabine and cyclophosphamide was performed for three consecutive days. After 1-day rest, subjects will receive a single dose infusion of RD133 at 1.0, 3.0, or 6.0x 10^6 CAR+ T cells/Kg. Subjects will be followed in the study for a minimum of 2 years after RD133 infusion. Long-term follow-up for lentiviral vector safety will be followed for up to 15 years after RD133 infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: January 1, 2037
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject must personally sign the written informed consent form approved by the ethics committee before the start of the study;

2. =18 years of age;

3. Have received at least 2 prior standard treatments, and achieved no response to the last-line treatment;

4. >25% Mesothelin positive rate on tumor cell membrane confirmed by prior immunohistochemistry of tumor tissue or freshly punctured tissue;

5. Expected survival = 12 weeks;

6. ECOG score = 2;

7. At least one measurable target lesion that meets the RECIST v1.1 standard;

8. Female or male subjects with fertility should agree to practice an effective method of contraception from the day of signing the ICF until 365 days after the infusion. Effective method of contraception is defined as: abstinence or contraceptive methods with an annual failure rate of <1% specified in the plan. ;

9. Before being enrolled in the group, the subject must have proper organ function and meet all of the following criteria:

9.1 The absolute value of neutrophils=1.0×10^9/L (granulocyte colony stimulating factor (G-CSF) support is allowed, but must be without supportive treatment within 7 days before the examination); 9.2 Platelet count =75×10^9/L (must be without blood transfusion support [including blood component transfusion] or thrombopoietin [TPO], or other treatments for the purpose of increasing platelets within 7 days before the examination); 9.3 Hemoglobin =9 g/dl (must be without blood transfusion support [including blood component transfusion] within 7 days before the examination); 9.4 Bilirubin value =1.5×upper limit of normal (ULN) (except bile duct obstruction caused by tumor compression); 9.5 Creatinine clearance rate =60 ml/min; 9.6 ALT or AST =2.5×upper limit of normal (ULN) (with liver involvement =5×ULN); 9.7 The results of echocardiography indicate that the cardiac ejection fraction is = 50%, without obvious pericardial effusion; 9.8 Stable coagulation function: INR = 1.5, APTT =1.2×ULN (except tumor-related anticoagulation therapy); 9.9 >91% basic blood oxygen saturation in the natural indoor air environments.

Exclusion Criteria:

1. Subject who has received any of the following prior treatments:

1.1 Subject with acute or chronic graft-versus-host disease (GVHD) who need systemic treatment within 4 weeks before enrollment; 1.2 Subject who has received gene therapy before enrollment; 1.3 Subject who needs systematic immunosuppressive therapy (except topical drugs) to control autoimmune diseases (eg: Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.), immunodeficiency or other diseases in the first 2 years after enrollment; 1.4 Subject who has been injected with live vaccines within 4 weeks before enrollment; 1.5 Subject has received other interventional clinical research drugs within 12 weeks before apheresis.

2. Subject with central metastasis or complete intestinal obstruction;

3. Subject with moderate or more severe hydrothorax and ascites which are hard to control by conventional treatment and require continuous catheter drainage;

4. With an active malignant tumor in the past 5 years, unless it is a curable tumor and has been obviously cured, such as basal or squamous cell carcinoma, cervical or breast carcinoma in situ, etc.

5. Subject with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and abnormal HBV DNA test results in peripheral blood (abnormal HBV DNA test results are defined as: HBV DNA quantitative level higher than the lower limit of the detection center or higher than normal range of the detection center; or qualitative HBV DNA test positive); Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus ( CMV) DNA test positive; syphilis test RPR positive.

6. With an uncontrollable active infection (except genitourinary system infection and upper respiratory tract infection <CTCAE Grade 2).

7. Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification = grade 3), severe arrhythmia.

8. Subject with hypertension that cannot be controlled by medication.

9. The toxicity of previous treatment has not been relieved to baseline or =1 (NCI-CTCAE v5.0, except for hair loss and laboratory abnormalities without clinical significance).

10. Major surgery within 2 weeks before enrollment, or has surgery planned during the time the subject is expected to be infused with RD133 or within 12 weeks after RD133 infusion (except planned surgery under local anesthesia).

11. Subject who has a solid organ transplant.

12. Women who are pregnant or breastfeeding.

13. Subject with previous central nervous system diseases (such as cerebral aneurysm, epilepsy, stroke, Alzheimer's disease, mental illness, etc.) or mental disorders.

14. Other unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney, or metabolic diseases that require medication.

15. Known to have life-threatening allergic reactions, hypersensitivity reactions or intolerances to RD133 cell preparations or its components.

16. Subject with hemorrhage, severe thrombosis judged by the Investigator, or hereditary/acquired hemorrhage and severe thrombosis (including hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.), or are receiving thrombolytic or anticoagulant.

17. The researcher believes that other situations are not suitable for inclusion in the group.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• RD133
The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFßRII receptors. dnTGFßRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.

Locations

Country	Name	City	State
China	The First Affiliated Hospital with Nanjing Medical University	Nanjing	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University	Shanghai IASO Biotechnology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Concentrations of TGF-ß	Measurement of TGF-ß level in peripheral blood	2 years post infusion
Other	Expression of biomarker in tumor tissue	The expression of CD3, CD4, CD8, CD68, CD163, MSLN, and PDL1 in tumor tissue after RD133 cell infusion	2 years post infusion
Other	Immunogenicity of RD133	The positive rate and antibody level of human anti-RD133 antibodies after RD133 cell infusion	2 years post infusion
Other	replication competent lentivirus (RCL)	The positive rate and change in replication competent lentivirus (RCL)	2 years post infusion
Other	Exploratory analysis of MSLN level in peripheral blood	The correlation between MSLN level in peripheral blood before and after RD133 cell infusion	2 years post infusion
Other	Exploratory analysis of MSLN level in tumor tissues and efficacy	The correlation between the expression level of MSLN in tumor tissues and clinical efficacy	2 years post infusion
Other	T/B/NK cell ratio in peripheral blood	T/B/NK cell ratio in peripheral blood will be measured using flow cytometry after RD133 cell infusion	2 years post infusion
Other	Systemic Cytokine Concentrations	Changes in the levels of inflammatory factors in peripheral blood after RD133 cell infusion	2 years post infusion
Primary	Type and incidence of dose-limiting toxicity (DLT) by dose group	The number and percentage of DLT in each dose group	2 years post infusion
Primary	Type and incidence of adverse events (AEs) and serious adverse events (SAEs) by dose group	Calculate type and incidence of adverse events (AE), serious adverse event (SAE), including those happened after lymphodepletion and after infusion, those related to study drug and lymphodepletion, or those that led to withdrawal from the study. They will also be aggregated by systematic organ classification (SOC), preferred term (PT), and severity.	2 years post infusion
Secondary	Number of Participants With Adverse Events	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product	2 years post infusion
Secondary	Objective response rate (ORR)	The proportion of subjects who have achieved best response of partial response (PR) or complete response (CR) according to the RECIST V1.1 evaluation criteria 3 months after RD133 cell infusion.	2 years post infusion
Secondary	Duration of response (DoR)	The time from the date of initial documentation of CR/PR after RD133 cell infusion to the date of progressive disease or death due to the disease studied	2 years post infusion
Secondary	Time to response (TTR)	The time from the date of RD133 cell infusion to the first efficacy evaluation of partial response (PR) or complete response (CR)	2 years post infusion
Secondary	Disease control rate (DCR)	The proportion of subjects with best efficacy assessment of complete response (CR), partial response (PR) or stable disease (SD)	2 years post infusion
Secondary	Progression-free survival (PFS)	The time from the date of RD133 cell infusion to the date of initial documentation of progressive disease/relapse or death from any cause	2 years post infusion
Secondary	Overall survival (OS)	The time from the date of RD133 cell infusion to the date of death	2 years post infusion
Secondary	Transgene Levels of RD133	Changes of virus vector copy number (VCN) in peripheral blood and tumor tissue (if any) after RD133 infusion	2 years post infusion
Secondary	Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration	Changes of CAR T cell concentration in peripheral blood and tumor tissue (if any) after RD133 infusion	2 years post infusion